Great news for kids regarding Corona.
All the vaccines giving protection against corona virus have come and vaccination is going on fast in India including the whole world. However, till now a big issue was about the health of the children and now this worry also seems to be ending soon. Great news for kids regarding Corona. Yes, let me tell you that recently there have been trials of Pfizer, after which it has been proved effective for emergency. Pfizer Inc and Bio NTech SE on Tuesday presented preliminary trial data for their COVID-19 vaccine in children aged 5 to 11 and said they would make formal requests with US regulators for emergency use in the coming weeks.
Simultaneously, according to data from the American Academy of Pediatrics, coronavirus infections among children increased in early September, reaching its highest point. The vaccine, which is already authorized in adolescents 12 to 15 years of age and fully approved for 16 years and older, showed a strong immunity in the target age group in a 2,268-participant clinical trial, prompted the response, the companies said on September 20. Pfizer and Bio N Tech are another step closer to seeking authorization for young children to receive the coronavirus vaccine, submitting data to the Food and Drug Administration that shows a “robust” antibody response and “favorable” safety outcomes in kids ages five to 11 who received the two-dose regimen in clinical trials.
The companies plan to submit a formal request for emergency use authorization of the vaccine for that age range “in the coming weeks,” they said Tuesday. News of the data submission comes a week after Pfizer announced promising results from the trials, which have been closely watched by parents eager to protect their children from the coronavirus. COVID-19 has now killed more than 690,000 people in the U.S., with millions more sickened by the disease. The Phase 1/2/3 trial initially enrolled up to 4,500 children ages 6 months to <12 years of age in the United States, Finland, Poland, and Spain from more than 90 clinical trial sites. It was designed to evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech vaccine on a two-dose schedule in three age group.
The trial enrolled children with or without prior evidence of SARS-CoV-2 infection. Pfizer and BioNTech have said that clinical trial results have shown that their corona vaccine is completely safe for children between the ages of five and 11 years and has increased immunity in children. The companies said that they will soon seek approval for the vaccine before the regulatory body. Sometimes it becomes difficult to explain to young children about masks and social distancing. In such a situation, the need for vaccine increases. The immune system will see this protein and an immune response will be generated. The immune system will create a memory so that it can be dealt with later in the event of a SARS-CoV-2 infection. This sequence is fixed and the genetic material of the mRNA vaccine is unlikely to remain in the host cell for long. One problem with this type of vaccine can be that high doses have to be taken for complete protection.